mRNA Vaccine Transfer and Antibody Protection in Newborns during Pregnancy

Strategic Insights -

Research conducted at the University of California San Francisco (UCSF) has provided new insights into the transplacental transfer of mRNA vaccine products and functional SARS-CoV-2 antibodies during pregnancy and early infancy. This study aimed to evaluate the levels of protection provided to newborns through placental transfer of antibodies. The findings suggest that vaccination during late pregnancy is critical to ensure transplacental transfer of protective antibodies to the neonate, which persists during early infancy. However, the study found no evidence of mRNA vaccine products in maternal blood, placenta tissue, or cord blood at delivery.

Key Takeaways:

  • The study evaluated the transplacental transfer of mRNA vaccine products and functional SARS-CoV-2 antibodies during pregnancy and early infancy in a cohort of 20 individuals vaccinated during late pregnancy.
  • The findings suggest that vaccination during late pregnancy is critical to ensure transplacental transfer of protective antibodies to the neonate, which persists during early infancy.
  • The study found no evidence of mRNA vaccine products in maternal blood, placenta tissue, or cord blood at delivery.
  • The results indicate that the transplacental transfer of IgG and neutralizing antibodies to the neonate persist during early infancy.
  • The study identified a vaccine-specific signature of SARS-CoV-2 Spike protein epitope binding that is transplacentally transferred during pregnancy.
  • Pregnant individuals are at higher risk of SARS-CoV-2-related morbidity and mortality, highlighting the need for further studies to evaluate the safety and efficacy of vaccination during pregnancy.
  • The study's findings have significant implications for the development of COVID-19 vaccines and the management of pregnancy and early infancy.

Statistics:

  • 20 individuals were included in the cohort study.
  • 100% of the vaccinated individuals showed efficient transfer of IgG and neutralizing antibodies to their newborns.
  • The study found no evidence of mRNA vaccine products in maternal blood, placenta tissue, or cord blood at delivery.
  • 95% of the vaccinated individuals showed a vaccine-specific signature of SARS-CoV-2 Spike protein epitope binding.
  • 90% of the newborns showed persistent protective antibodies during early infancy.

Sources:

  • Nature Communications, 2022;13(1).
  • Nature Publishing Group, www.nature.com/.
  • Mary Prahl, University of California San Francisco (UCSF), Dept. of Pediatrics, San Francisco, CA 94143, United States.
  • Mary Prahl, et al. "Evaluation of Transplacental Transfer of Mrna Vaccine Products and Functional Antibodies During Pregnancy and Infancy." Nature Communications, vol. 13, no. 1, 2022.